GGrantIndex
← Leaderboards

Gary V. Desir

Yale University

Google Scholar ↗PubMed ↗ORCID ↗
$8,576,842
Attributed
$13,361,626
Total exposure
13
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,361,626 · 13

By mechanism

R01$5,947,119 · 4
R44$4,889,361 · 2
R43$1,196,926 · 3
RC1$1,000,000 · 2
R41$219,130 · 1
P50$109,090 · 1

Top collaborators

Most similar at Yale University

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo”

Research focus

In VivoPathway InteractionsPharmaceutical PreparationsIn VitroInjuryKidneySignal TransductionPeptidesMacrophagePlasmaNovel TherapeuticsAnimal ModelMouse ModelFutureTissuesAffectCell SurvivalRecombinantsAcuteProteinsEnzyme-Linked Immunosorbent AssayKnockout MiceBloodMortality

Grant awards (31)

Development of a novel renalase agonist for the treatment of acute pancreatitis$903,732
R44 · FY2025 · DK
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists$296,931
R43 · FY2024 · AI
New target and new therapy for severe Covid-19 and viral hyperinflammation damage: renalase and renalase agonists$299,999
R43 · FY2023 · AI
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$672,231
R44 · FY2022 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors$1,327,758
R44 · FY2021 · CA
Renalase inhibition for treatment of unresectable melanoma$481,477
R01 · FY2021 · CA
Renalase: Development as an Innovative New Drug for Acute Pancreatitis$1,136,337
R44 · FY2020 · DK
Renalase inhibition for treatment of unresectable melanoma$481,894
R01 · FY2020 · CA
Renalase: Development as an Innovative New Drug for Acute Pancreatitis$849,303
R44 · FY2019 · DK
Renalase inhibition for treatment of unresectable melanoma$470,539
R01 · FY2019 · CA
Renalase inhibition for treatment of unresectable melanoma$491,209
R01 · FY2018 · CA
Humanized Anti-Renalase Antibodies for Unresectable Melanoma$299,996
R43 · FY2018 · CA
Renalase inhibition for treatment of unresectable melanoma$490,257
R01 · FY2017 · CA
Acute Pancreatitis: Renalase as a novel target and agonists as new therapy$300,000
R43 · FY2016 · DK
Therapeutic Utility of renalase and renalase peptides in cisplatin-mediated renal$219,130
R41 · FY2014 · CA · contact PI
RENALASE DEFICIENCY AND CARDIOVASCULAR COMPLICATIONS OF CHRONIC KIDNEY DISEASE$500,000
RC1 · FY2010 · DK · contact PI
RENALASE IN ACUTE KIDNEY INJURY: UTILITY AS A BIOMARKER, AND THERAPEUTIC AGENT$500,000
RC1 · FY2010 · DK · contact PI
The Molecular Physiology of Renalase$321,088
R01 · FY2010 · DK · contact PI
The Molecular Physiology of Renalase$324,500
R01 · FY2009 · DK · contact PI
Regulation of Glucose Homeostasis by the Kv1.3 Channel$239,916
R01 · FY2008 · DK · contact PI
Regulation of Glucose Homeostasis by the Kv1.3 Channel$244,813
R01 · FY2007 · DK · contact PI
Regulation of Glucose Homeostasis by the Kv1.3 Channel$252,124
R01 · FY2006 · DK · contact PI
Regulation of Glucose Homeostasis by the Kv1.3 Channel$258,192
R01 · FY2005 · DK
Structure, Function and Regulation of Renal K Channels$234,912
R01 · FY2005 · DK
Regulation of Glucose Homeostasis by the Kv1.3 Channel$258,192
R01 · FY2004 · DK
Structure, Function and Regulation of Renal K Channels$234,912
R01 · FY2004 · DK
Structure, Function and Regulation of Renal K Channels$234,912
R01 · FY2003 · DK
Structure, Function and Regulation of Renal K Channels$304,885
R01 · FY2002 · DK
FUNCTION AND REGULATION OF CGMP GATED RENAL K+ CHANNELS$316,254
R01 · FY2001 · DK
FUNCTION AND REGULATION OF CGMP GATED RENAL K+ CHANNELS$307,043
R01 · FY2000 · DK
MOLECULAR BIOLOGY AND PATHOPHYSIOLOGY OF A CAMP REGULATED POTASSIUM CHANNEL$109,090
P50 · FY2000 · HL